Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evogliptin - Dong-A ST

Drug Profile

Evogliptin - Dong-A ST

Alternative Names: DA-1229; SUGANON; Sugarnon

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Alkem Laboratories; Dong-A ST; Eurofarma; GEROPHARM; Luye Pharma Group; Tobira Therapeutics
  • Class Amides; Antihyperglycaemics; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Aortic valve stenosis
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Nov 2019 Dong-A ST plans a phase III trial for Type 2 diabetes mellitus (Adjunctive treatment) in South Korea (PO) (NCT04170998)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(Combination therapy, In volunteers) in USA
  • 26 Aug 2019 Phase-II clinical trials in Aortic valve stenosis in South Korea (PO) (NCT04055883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top